Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Home Newsfeeds JP Morgan Maintains Overweight on Amazon.com, Raises Price Target to $185

JP Morgan Maintains Overweight on Amazon.com, Raises Price Target to $185

JP Morgan analyst Doug Anmuth maintains Amazon.com (NASDAQ:AMZN) with a Overweight and raises the price target from $175 to $185.

byBenzinga Newsdesk

July 29, 2022

1 minute read

JP Morgan analyst Doug Anmuth maintains Amazon.com (NASDAQ:AMZN) with a Overweight and raises the price target from $175 to $185.

DA Davidson Initiates Coverage On Waldencast with Buy Rating, Announces Price Target of $12

By Benzinga Newsdesk

September 9, 4:32 AM

DA Davidson analyst Linda Bolton Weiser initiates coverage on Waldencast (NASDAQ:WALD) with a Buy rating and announces Price Target of $12.

WALD

News

Lyell Immunopharma Says Termination of GSK Agreement Has Minimal Impact To Co.’s Operations, Says Termination Is Effective On Dec. 24, 2022

By Michael Horton

October 24, 5:32 PM

-Reuters

GSK

Congress Journalist For Politico Nicholas Wu Tweets “And It’s Official – Dems Urged To Vote No On A Motion To Adjourn (If It Comes Up)”

By Benzinga Newsdesk

January 4, 12:51 PM

https://twitter.com/nicholaswu12/status/1610679345193914381

SPY

23andMe Therapeutics Present Preliminary Phase 2 Safety And Efficacy Results For 23ME-00610, Targeting CD200R1, At The 2024 ASCO Annual Meeting

By Benzinga Newsdesk

June 3, 8:21 AM

– 23ME-00610 monotherapy demonstrates preliminary evidence of clinical benefit, including one confirmed partial response – 23ME-00610 monotherapy continues to demonstrate acceptable safety and tolerability, and

JP Morgan Maintains Overweight on Amazon.com, Raises Price Target to $185

Related Posts

DA Davidson Initiates Coverage On Waldencast with Buy Rating, Announces Price Target of $12

Lyell Immunopharma Says Termination of GSK Agreement Has Minimal Impact To Co.’s Operations, Says Termination Is Effective On Dec. 24, 2022

Congress Journalist For Politico Nicholas Wu Tweets “And It’s Official – Dems Urged To Vote No On A Motion To Adjourn (If It Comes Up)”

23andMe Therapeutics Present Preliminary Phase 2 Safety And Efficacy Results For 23ME-00610, Targeting CD200R1, At The 2024 ASCO Annual Meeting